Rhenman & Partners Asset Management AB - ADVERUM BIOTECHNOLOGIES INC ownership

ADVERUM BIOTECHNOLOGIES INC's ticker is ADVM and the CUSIP is 00773U108. A total of 97 filers reported holding ADVERUM BIOTECHNOLOGIES INC in Q1 2018. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
Rhenman & Partners Asset Management AB ownership history of ADVERUM BIOTECHNOLOGIES INC
ValueSharesWeighting
Q1 2021$6,409,000
-5.4%
650,000
+4.0%
0.45%
-19.2%
Q4 2020$6,775,000
+5.2%
625,0000.0%0.55%
-3.3%
Q3 2020$6,438,000
-38.3%
625,000
+25.0%
0.57%
-49.3%
Q2 2020$10,440,000
+94.3%
500,000
-9.1%
1.13%
+49.8%
Q1 2020$5,374,000
-28.2%
550,000
-15.4%
0.75%
-8.3%
Q4 2019$7,488,000
+1048.5%
650,000
+443.1%
0.82%
+901.2%
Q3 2019$652,000
-54.2%
119,6730.0%0.08%
-47.8%
Q2 2019$1,423,000
+127.0%
119,6730.0%0.16%
+115.1%
Q1 2019$627,000
+66.3%
119,6730.0%0.07%
+69.8%
Q4 2018$377,000
-59.5%
119,673
-22.3%
0.04%
-53.8%
Q3 2018$931,000
+14.1%
153,9650.0%0.09%
+10.7%
Q2 2018$816,000
+10.7%
153,965
+21.2%
0.08%
-7.7%
Q1 2018$737,000
+65.6%
127,0060.0%0.09%
+51.7%
Q4 2017$445,000
-20.8%
127,006
-17.5%
0.06%
-16.7%
Q3 2017$562,000
+46.0%
154,0060.0%0.07%
+30.9%
Q2 2017$385,000
-7.5%
154,0060.0%0.06%
-16.7%
Q1 2017$416,000
-6.9%
154,0060.0%0.07%
-23.3%
Q4 2016$447,000
-99.9%
154,0060.0%0.09%
-14.9%
Q3 2016$632,965,000
+129872.3%
154,0060.0%0.10%
+17.4%
Q2 2016$487,000154,0060.09%
Other shareholders
ADVERUM BIOTECHNOLOGIES INC shareholders Q1 2018
NameSharesValueWeighting ↓
BML Capital Management, LLC 3,915,000$5,872,5005.39%
Versant Venture Management, LLC 5,068,233$7,602,3504.04%
Sonic GP LLC 2,000,000$3,000,0002.91%
COMMODORE CAPITAL LP 10,000,000$15,000,0001.75%
VR Adviser, LLC 6,573,300$9,859,9501.04%
AIGH Capital Management LLC 1,323,985$1,985,9770.94%
Newtyn Management, LLC 1,025,000$1,537,5000.38%
Worth Venture Partners, LLC 331,668$497,5020.30%
Acuitas Investments, LLC 291,169$436,7540.26%
Quinn Opportunity Partners LLC 398,298$597,4470.08%
View complete list of ADVERUM BIOTECHNOLOGIES INC shareholders